Overcoming Challenges to Gene Therapy Manufacturing Workshop

Gene therapy clinical trials pose interesting challenges in GMP manufacturing. Plasmids and vectors often cannot be produced by the same vendors, may have different stabilities, and may require different storage conditions. Furthermore, some gene therapies require additional processing of the vector with target cells ex vivo. This expert-led session will explore innovations and best practices that are shortening timelines, lowering costs, and standardizing processes when manufacturing gene therapies.

Chair:
Anthony Gringeri, Ph.D., Strategic Advisor, Cell One Partners

Speakers:
David Backer, Chief Commercial Officer, Oxford Biomedica
Michelle Berg, President, GMP Nucleic Acids, Aldevron
Fabian Gerlinghaus, Co-Founder and CEO, Cellares
Judith Koliwer, Ph.D., Lead Consultant Software, Körber Business Area Pharma